Wartremoverointment

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the removal of genital warts, plantar warts, common warts, and flat warts. Common warts are characterized by their rough, "cauliflower-like" surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting tenderness and disrupting the normal footprint pattern.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should advise patients to avoid exposure to fire and flame during use. Proper precautions should be taken to ensure safety while administering the product.

Contraindications

Use is contraindicated in the following situations:

• Patients experiencing chest pain, rapid heartbeat, faintness, or dizziness.

• Patients with sudden, unexplained weight gain.

• Patients with swelling of the hands or feet.

• Patients exhibiting scalp irritation or redness.

• Patients with unwanted facial hair growth.

• Patients who do not observe hair regrowth within 4 months of use.

• Pregnant or breastfeeding individuals, due to potential harm.

• Application on broken or irritated scalp is contraindicated.

Warnings and Precautions

For external use only, this product must be handled with caution. It is imperative to keep it away from fire and flame to prevent any potential hazards.

Healthcare professionals should advise patients to discontinue use and seek medical attention if any of the following symptoms occur: chest pain, rapid heartbeat, faintness, or dizziness. Additionally, patients should be instructed to stop use if they experience sudden, unexplained weight gain, swelling of the hands or feet, scalp irritation or redness, unwanted facial hair growth, or if there is no observable hair regrowth after four months of treatment.

This product may pose risks if used during pregnancy or while breastfeeding; therefore, it is essential to counsel patients regarding these potential dangers. Furthermore, it should be kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Patients should also be advised to discontinue use if the scalp is broken or irritated, as this may exacerbate adverse effects. Regular monitoring of the scalp condition and patient symptoms is recommended to ensure safe and effective use of the product.

Side Effects

Patients should be advised that the product is for external use only and must be kept away from fire and flame to prevent serious hazards.

In clinical practice, it is important to instruct patients to discontinue use if the product comes into contact with a broken or irritated scalp, as this may lead to adverse reactions. Monitoring for any signs of irritation or adverse effects is recommended to ensure patient safety.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified for this product. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Wartremoverointment (wart remover ointment). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is recommended.

This product is contraindicated for use on broken or irritated scalp in pediatric patients. The application procedure may be repeated once or twice daily as needed until the wart is removed, with a maximum duration of treatment up to 12 weeks.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Use of this medication during pregnancy may pose risks to the developing fetus. Animal studies have indicated potential harm, and there is insufficient data from controlled human studies to fully assess the risks. Therefore, it is recommended that pregnant patients avoid using this medication unless the potential benefits outweigh the risks.

Additionally, breastfeeding is not advised while using this medication, as it may be harmful to a nursing infant. Healthcare professionals should counsel women of childbearing potential regarding the potential risks associated with the use of this medication during pregnancy and lactation.

Lactation

Lactating mothers should be aware that the use of this medication may be harmful during breastfeeding. There is insufficient data regarding the excretion of this drug in human breast milk and its potential effects on breastfed infants. Therefore, caution is advised when considering the use of this medication in lactating individuals. It is recommended that healthcare professionals evaluate the risks and benefits before prescribing this medication to nursing mothers.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the lack of detailed overdosage data necessitates a vigilant approach. Symptoms may vary depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement standard supportive care measures, which may include the following:

1. Assessment: Conduct a thorough evaluation of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide symptomatic treatment as necessary, which may involve intravenous fluids, oxygen supplementation, or other interventions based on the patient's needs.

3. Consultation: Engage with a poison control center or toxicology expert for guidance on specific management strategies tailored to the situation.

Due to the lack of specific overdosage information, it is imperative for healthcare professionals to remain vigilant and prepared to manage any complications that may arise from an overdose scenario.

Nonclinical Toxicology

May be harmful if used during pregnancy or breastfeeding. No non-teratogenic effects have been specified. There are no additional details provided regarding nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. Instruct patients that if the medication is swallowed, they should seek medical help or contact a Poison Control Center immediately at 1-800-222-1222.

Additionally, it is important to inform patients that the medication may be harmful if used during pregnancy or while breastfeeding. Providers should encourage patients to discuss any potential risks with their healthcare team to ensure safe use.

Storage and Handling

The product is available in various package configurations, identified by the National Drug Code (NDC) numbers. Specific storage instructions, disposal guidelines, safe handling warnings, environmental warnings, and additional safety information have not been provided. As such, no particular temperature ranges, container requirements, or special handling needs are specified for this product. Healthcare professionals are advised to follow standard practices for the storage and handling of pharmaceutical products.

Additional Clinical Information

The product is administered cutaneously, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should advise patients to keep the product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Wartremoverointment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)